Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NIPP1 CRISPR/Cas9 KO Plasmid (h): sc-406193
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NIPP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NIPP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NIPP1 Antibody (A-11): sc-393991
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NIPP1 CRISPR/Cas9 KO Plasmid (h) | sc-406193 | 20 µg | $397.00 |
Overview
PPP1R8 encodes nuclear inhibitor of protein phosphatase 1 (NIPP1), a multifunctional regulatory subunit that modulates PP1-dependent dephosphorylation within the nucleus. NIPP1 participates in control of transcriptional programs, pre-mRNA splicing, and cell-cycle–linked chromatin processes by coordinating phosphatase activity with RNA- and chromatin-associated complexes. Through these roles, PPP1R8 contributes to maintenance of nuclear signaling fidelity and genome regulatory states that influence proliferation and stress responses. Altered regulation of PP1 signaling and nuclear phospho-control pathways involving NIPP1 has been examined in contexts relevant to tumor biology and other disorders of dysregulated growth and differentiation.
NIPP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PPP1R8 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PPP1R8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PPP1R8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NIPP1 protein expression.
This CRISPR knockout system enables efficient generation of PPP1R8-deficient cell models for investigation of NIPP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PPP1R8 exon(s) critical for NIPP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PPP1R8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NIPP1 CRISPR/Cas9 KO Plasmid (h) and NIPP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PPP1R8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NIPP1 HDR Plasmid (h) and NIPP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PPP1R8 homology arms to support homology-directed repair at defined PPP1R8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.